Managing your weight is a hard task no matter your age. But as we age there are extenuating factors that make weight loss even harder. Lifestyle factors, having a desk job, less physical activity, hormone changes e.g. insulin sensitivity or sleep deficiency. While exercise and healthy eating are vital for weight loss, sometimes that’s easier said than done! That’s where we come in. You set the Resolution and we find you the Solution!
Strengths of our study include the serial physiologic assessments before and after bariatric surgery. The gastric bypass procedure ensured a large degree of weight loss (≈27% mean change in BMI), while the administration of normal saline provided an acute stimulus for eliciting acute natriuretic peptide responses. Thus, we were able to compare the relative effects of weight loss and saline infusion, with each individual serving as his or her own control. This study design minimizes confounding from sources of natriuretic peptide variation that might correlate with BMI. We performed the post‐surgical assessment 6 months after surgery to ensure that acute hemodynamic changes from surgery had resolved and patients had attained most of their expected weight loss. Mitral annular early diastolic (e′) velocity at the lateral annulus has been accepted as an index of diastolic function24, 25 and we had significant improvement in e′ suggesting improvement in myocardial relaxation. Our echocardiographic findings are in accordance with the recently published meta‐analysis demonstrating benefits of bariatric surgery on diastolic function.26
Prof. Gary Wittert, Adelaide-based Principal Investigator on the study, said: “As the world’s first drug with a metabolic mechanism of action AOD9604 could occupy a unique position among the options available to doctors for the management of obesity. It is pleasing that the invention and its development from the laboratory bench has been an all–Australian effort.”
Also, as we age, our metabolic processes slow down, leading to less background energy consumption. Less exercise promoting muscular strength gets exchanged for walking and taking the stairs. This reduces muscle that burns fat and increases the metabolism again causing fat storage due to lack of activity. The result is obesity, which is now a pandemic.
Press coverage and word of mouth has generated quite a bit of hype around AOD9604. Despite its popularity on the black market, there is no research into the safety and effect of injecting this peptide at high doses. Intriguingly, it is not currently in Calzada's interest to fight the black market production of AOD9604, even though it is a patented product. Calzada lack the funds to legitimately boost the reputation of this peptide through clinical trials, and there is a strong chance these would once again prove that AOD9604 has no effect. The good reputation this peptide currently enjoys is likely to provide strong leverage to its marketing as a food supplement in the United States.
By increasing our own growth hormone levels (which normally decrease as we age), there is an increase in protein synthesis which subsequently stimulates muscle growth. It leads to an increase in muscle mass, an increase in fat metabolism (fat loss), and increase in physical strength. It is also helpful in skin ageing, and effective in reducing wrinkles.
The first reason is that CJC-1295 DAC is a GHRH (growth hormone releasing hormone) acting directly at the pituitary, while GHRP products indirectly stimulate GH by causing the release of Ghrelin. Rotating the products would therefore ensure one method of GH stimulation does not get "worn out" from repeated exposure to the peptides. The second reason is that even though CJC-1295 DAC has been proven safe in much higher dosages than we recommend, since it causes a continual GH release (GH bleed) no one can be certain how continual use would affect the pituitary in the long-term, so it's a case of being "better safe than sorry" and never using it for longer than 6 months at a time without a break.
Peptides are defined as a compound of two or more amino acids in which a carboxyl group of one is united with an amino group of another. With the elimination of a water molecule, a peptide bond is formed. To put it more simply, peptides are just small proteins. When the number of amino acids are less than 50, these are peptides. When higher than 50, these are proteins. The peptides are therefore small chains of amino acid which are present in all cells of the body. There are several kinds of peptides: oligopeptides, polymers, proteins, neuropeptides and peptide hormones. These are synthesized naturally by the body. Peptides will therefore be used primarily to make a more abundant amount of hormones in the body. The latter will then produce new hormones such as Testosterone or corticosteroids. It is these two hormones that are considered anabolic or indirect anti-inflammatory.
Causing one to be " hungry as a wolf " and having a strong gastric motility, this 1er injectable peptide is interesting for fitness practitioners who may require support to finish their carefully prepared meals. This sudden increase in appetite that occurs around 20 minutes after the injection is related to the fact that GHRP-6 stimulates the release of a digestive hormone, Ghrelin, which is designed to cause hunger pangs. This makes it a valuable ally in weight gain treatments , which is important.
Your level of physical activity also affects IGF-1, and heavy weight training for your legs is a particularly potent way to increase it. Some studies suggest that the effects of the popular anti-aging supplement DHEA actually arise due to this same type of increase in IGF-1 in the body that occurs with with weight training (so you choose: heavy barbell squats or a bottle of DHEA from the drugstore).
The particle size of a drug molecule is a crucial factor in the effects of intra-articular injections. The larger the particle size, the longer the drug will stay in a joint, thereby increasing its efficacy . The short residence time of intra-articular AOD9604 when dissolved in saline was due to its rapid uptake by local circulation. However, the combination of AOD9604 with HA may result in more residence time and better effects in the joint. Recent studies [21–23] have shown that the addition of HA to nanoparticles improves the drug effects by increasing drug bioavailability and decreasing systemic absorption after topical administration.
The four groups showed different gross morphological damage and histopathological changes in the cartilage of the lateral part of the femoral condyle (Figure 3). Complete disorganization of articular cartilage with apparent cloning of chondrocytes in the transitional and radial zones was evident in Group 1 (Figures 3-A,E,I). Abnormal gross morphological and histopathological changes such as fibrillated and irregular cartilage surfaces, disappearance of surface-layer cells, and slightly diffused cell growth in the transitional and radial zones were observed in Group 2 (Figures 3-B,F,J). Erosion of the articular cartilage, cleft, and cell cloning in the transitional and radial zones were noted in Group 3 (Figures 3-C,G,K). Softening of articular cartilage and surface irregularities were noted in Group 4 (Figures 3-D,H,L).
2. If HGH can be obtained legally from a physician for anti-aging it's extremely expensive, with 10iu (units) costing as much as $200USD. As a comparison, the 10iu equivalent of GH releasing peptides (approximately half of one vial) sells online for approximately $20USD, a full 90% cheaper than actual HGH for the same, if not better, positive effects on the body.
As a general rule, regardless of your goal, if you are just looking to take one product, with the least amount of fuss and injections as possible, then it should be CJC-1295 DAC at 2mg (1 vial) per week. Due to its long half-life it causes your overall level of GH (Growth Hormone) to rise, and you will therefore see some improvements in things which go along with having higher levels of GH and IGF-1 such as improved body shape, sleep, skin and general wellbeing (although it can make you tired for the first 1-2 weeks while the body adjusts). Your dosage can be taken as just one injection per week (note that you may notice a head rush/flushing for 15-20 minutes after your injection due to the release of GABA in the body, a sign the product is working).
IGF-1 is so named because of its close resemblance to insulin. Because IGF-1 is so similar to insulin, it interacts with insulin receptors on the surface of your cells, produces some of the same effects as insulin and even magnifies the effect of insulin. For example, one primary effect of both excess insulin and excess IGF-1 is hypoglycemia (low blood glucose). When you workout for a long time (longer than about one hour) your liver increases its release of IGF-binding protein (IGFBP-3) to prevent the onset of hypoglycemia that would otherwise happen as a result of the increased release of IGF-1 that occurs during training.
There were no changes in laboratory parameters or vital signs in any treatment group. There were no clinically significant abnormalities in vital signs, safety tests, or ECGs during the studies. At no time were statistically significant differences in IGF-1 levels among the treatment groups and placebo detected. The overall mean changes in IGF-1 were 1.76 nmol/L and 1.24 nmol/L after 12 and 24 weeks of treatment, respectively. There were no statistically significant differences between the treatment groups or placebo (P = 0.50844 after 12 weeks and P = 0.75754 after 24 weeks).
Serum IGF-1 levels remained relatively constant over the dosing period with no apparent differences between treatment groups. Fasting plasma glucose and serum insulin levels remained unchanged throughout the treatment period. Furthermore, no changes in any of the OGTT parameters were observed from day 1 to day 7 of treatment. There were no study related clinically significant findings in the safety related laboratory tests, vital signs, or ECG measurements.
“We are delighted with these results,” stated Metabolic Pharmaceuticals CEO, Chris Belyea. “The evidence from the trial is that over 12 weeks AOD9604 induces competitive weight loss with accompanying health benefits at a low dose and has superior tolerability. Our next major focus is a partnership with a major pharmaceutical company to assist in financing late stage longer term human clinical trials for worldwide marketing approval as a prescription treatment.”
Metabolic has just completed Phase IIA studies in a group of 22 clinically obese, but otherwise healthy, male patients ranging in age from 22?50. The results showed that the drug was well tolerated and increased fat metabolism within two hours of administration by 25 per cent in the older group of patients. Although not the focus of the study, weight loss was also demonstrated, particularly in the older group.
In summary, our study provides evidence of an alteration in the natriuretic peptide “set point” with weight loss. These findings highlight the potential role of a “natriuretic peptide deficiency” in obesity‐related conditions such as hypertension and heart failure. One can further speculate that reversal of the “natriuretic peptide deficiency” could play a role in the improvement of blood pressure and cardiac function after weight loss.
Growth Hormone Releasing Peptides (GHRP): include Ipamorelin, GHRP-2 and GHRP-6, peptides which stimulate the release of a hormone called "Ghrelin" in the stomach, which then in turn causes GH to be released. GHRP's cause a much more significant release of GH than do GHRH, meaning that mg for mg, a peptide like GHRP-6 is three times more potent than Modified GRF 1-29. However, when taken together, they become approximately ten times more potent than either one alone.
AOD is a peptide 15 amino acids long which mimics a small portion of the growth hormone that has the fat reducing effects (increases fat metabolism). It works by mimicking the way natural growth hormone regulates fat metabolism but without the adverse effects on blood sugar and growth that is seen if unmodified growth hormone is given. It stimulates lipolysis (break down of fat) and inhibits lipogenesis (non fat food being stored in the body as fat).
The mean time (± SD) taken for recovery of normal ambulation was 25±2 days in Group 1, 15±3 days in Group 2, 16±2 days in Group 3, and 11±4 days in Group 4. The lameness period in Group 4 was significantly shorter than those in Groups 1, 2, and 3 (p<0.05). The lameness period in Group 1 was significantly longer than those in Groups 2 and 3 (p<0.05). However, there were no differences in the mean lameness period between Groups 2 and 3 (Figure 6).
Cartilage loss in OA is caused by proteoglycan depletion and chondrocyte death that in turn are caused by imbalances between catabolic and anabolic activities within the joint . Growth hormone (GH) has been shown to correct this imbalance . Although the exact mechanism underlying the effects of intra-articular GH injection is not known, GH in the synovial fluid probably enhances proliferation, matrix synthesis, and differentiation of bone and cartilage cells in vitro . Studies have found that GH accelerates healing in animal models of OA [8,9]. However, intra-articular GH injections in humans are known to have detrimental pro-tumor and pro-diabetic effects. These negative effects are caused by the secondarily produced insulin-like growth factor-1 (IGF-1) .
The peptide therapy protocols (Amino Acid Analogs) prescribed by TeleWellnessMD providers are also known as secretagogues (pronounced se-creta-gog), a substance that promotes secretion. These amino acid chains communicate with the body to produce or release growth hormone. Hence a secretagogue causes the body’s own natural processes to produce growth hormone. Secretagogues do not act as growth hormones but rather stimulate the pituitary gland to secrete your stored growth hormone. The subcutaneous injection route of growth hormone stimulation is a preferred route to help slow down age and environmental reductions in growth hormone levels.
ASADA gave advice to the ACC, and perhaps Essendon, that AOD-9604 was not banned under the S2 category. Given the expectation that AOD-9604 would not be anabolic because it lacked the ''anabolic region'' of HGH, it is perhaps understandable that ASADA did not classify it under S2 in 2011 and 2012, although its close structural relationship to the banned HGH should have been sufficient to include it on the banned list.
The DAC technology in the CJC-1295 enables the compound to bind itself covalently with any circulating albumin, after it has been administered through a subcutaneous injection. However, the reason why the half-life could be extended from a few minutes to several days is more profound. The reactive group in the CJC-1295 binds to a peptide through bioconjugation. The peptide then finds a neucleophilic unit within the blood and reacts with it in order to create a firmer bond.
Without side effects with an appropriate assay, this peptide contributes to fat loss and muscle gain. CJC-1295 DAC could interest those wishing to rarely perform injections due to a stable rate over time rather than intermittent dosages, that provides the maximum necessary for optimal effect. Its use combined with a GHRP is interesting but not as much as with MOD-GRF whose peaks of free GHRH peptides would be coordinated with the GHRP associated.
Another side effect of the CJC-1295 is acromegaly, since it helps in increasing the levels of the growth hormone. Acromegaly is a condition where extra growth hormone is released even after the internal organs and the skeleton have finished growing. This causes thickening of the skin, deepening of voice, enlargement of jaws, and slurring of speech. Another effect of acromegaly is the swelling of the soft tissue in the internal organs. This could result in the weakening of the muscles of the internal organs, like the heart. This was tested during the phase 2 testing of CJC-1295.
At the time that decision was made, paracetamol/caffeine combinations were available over-the-counter in over 50 other countries and had been exempt from scheduling in a number of major markets that are similar to Australia in terms of population type and regulatory status. Experience with the unscheduled sale of this product was extensive: UK 19 years, Ireland 12 years and New Zealand for 7 years. However, the Committee determined not to consider paracetamol combined with caffeine for exemption from scheduling until market experience had been gained with use as a Schedule 2 product in Australia.
Results: AOD 9604 had no effect on serum IGF-1 levels, which confirms the hypothesis that AOD 9604 does not act via IGF-1. Results of oral glucose tolerance test demonstrated that, in contrast with hGH, AOD 9604 has no negative effect on carbohydrate metabolism. There were no anti-AOD 9604 antibodies detected in any of the patients selected for antibody assay. In none of the studies did a withdrawal or serious adverse event occur related to intake of AOD 9604.
Peptide therapy encompasses numerous different drugs with varied effects, ranging from immune modulation and tissue repair to fat loss and muscle building. Our center has seen very positive results in patients with CFS, Hashimoto’s thyroiditis, Lyme disease, and fibromyalgia, among other conditions. Ask your physician or speak to a patient representative at (877) 508-1177 to find out if peptide therapy is right for you.
For CJC-1295 DAC there are no particular diet restrictions that need to be followed due to its long half-life. For GHRP products the following should be observed as insulin and fatty acids can blunt the release of GH in the body and therefore make your injections less effective: •Avoid eating/drinking anything high in fat for 3 hours before your injection and anything high in carbohydrates for 1-2 hours (always do your injection on an empty stomach). •Wait at least 20 minutes after your injection before eating/drinking anything with calories.
When taking Ipamorelin, you want it to be pushed through your system naturally, and at the same levels. If you are constantly altering the times you take it, or increase/decrease dosages during your cycle, this is not going to be attainable. To maximize the benefits and gains you are going to experience, dosage levels should be consistent, as should the timing of the dosage you are taking each day.
CJC1295: A growth hormone-releasing peptide, CJC1295 was first made by a Canadian biotechnology company to reduce fat deposits in obese AIDS patients. Research has shown that almost 100% of people injected with CJC1295 experienced side effects such as high blood pressure, diarrhoea, and headaches. There is no published evidence that CJC1295 produces any benefit to athletes. There is little or no peer-reviewed evidence that CJC1295 gives any advantage in sports, and as a growth hormone-releasing substance, is banned by WADA.
In addition, scientists have observed that those who supplemented with IGF-1 experienced a preponderance of new brain cell growth and new muscle mass and new studies confirmed this to be true, even among individuals with both brain damage and muscle-wasting sarcopenia. Furthermore, research studies have found IGF-1 to increase feelings of youthfulness, improve well-being, and even to alleviate depression.
GHRP + GHRH (twice per day) ◦Inject your GHRP + GHRH peptides together in the same syringe (ensuring you have not consumed any food/beverages for at least 1 hour before, an optimal time would be first thing in the morning). ◦Ingest a protein only or protein and carbohydrate meal afterward to create an insulin spike. ◦Do weight training in the hours afterwards. ◦at least 1 hour after your dinner (or last meal of the day), take your second GHRP + GHRH injection. ◦If you are trying to control your body fat then have a protein only meal 20-30 minutes afterwards, otherwise a protein/carbohydrate meal will create a better insulin spike.
A study research coordinator screened charts for eligibility from a pool of patients who were referred to the weight center of the Massachusetts General Hospital for Roux‐en‐Y gastric bypass surgery. Eligible patients were informed about the details of the research protocol, including the need for 2 saline infusion visits at the Clinical Research Center (CRC) 6 months apart. A study physician investigator verified the medical history of study participants including the use of medications at the time of the saline protocol visit. The subjects were asked to keep a detailed diary of all the food and beverages consumed for the 48 hours prior to each study visit to estimate their nutritional status.
Figure 1A shows the chronic effect of saline, AOD9604, and hGH in lean C57BL/6J mice on body weight and food intake. The hGH potently increased the body weight gain of these mice, reaching significance by d 8. There was an increase in body weight after AOD9604 only on the last day of treatment. In contrast, ob/ob mice (Fig. 1B) showed a profound decrease in body weight after both AOD9604 and hGH. Importantly, these effects were not attributed to changes in food intake in either the lean or the ob/ob mice (Fig. 1, C and D, respectively).
One submission was received, which did not support the delegate's interim decision, as available data support that the fixed dose paracetamol/caffeine combination product provides clinically meaningful efficacy over paracetamol alone; has an excellent safety profile; a very low risk of nephrotoxicity, toxicity in overdose, misuse, abuse or illicit use; and a highly favourable risk/benefit profile.
Peptides are a generic name given to any group of amino acids that are linked together to form a chain. Essentially, they are similar to proteins, though in much shorter lengths (less than 50 units long). In the world of bodybuilding and exercise science, peptides generally refer to one of two things. They can refer to either broken protein fragments from hydrolysed proteins, or peptide hormones and related compounds.